Y Intercept Hong Kong Ltd Sells 25,369 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)

Y Intercept Hong Kong Ltd cut its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 64.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 13,823 shares of the company's stock after selling 25,369 shares during the period. Y Intercept Hong Kong Ltd's holdings in Denali Therapeutics were worth $403,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in DNLI. Wellington Management Group LLP grew its holdings in shares of Denali Therapeutics by 9.2% in the third quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company's stock worth $312,491,000 after purchasing an additional 903,683 shares during the last quarter. FMR LLC grew its holdings in Denali Therapeutics by 3,234.3% in the 3rd quarter. FMR LLC now owns 7,831,378 shares of the company's stock worth $228,128,000 after acquiring an additional 7,596,508 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Denali Therapeutics by 63.2% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,749,486 shares of the company's stock valued at $109,223,000 after acquiring an additional 1,451,770 shares during the period. Marshall Wace LLP raised its stake in shares of Denali Therapeutics by 12.7% during the second quarter. Marshall Wace LLP now owns 2,418,833 shares of the company's stock valued at $56,165,000 after acquiring an additional 272,454 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Denali Therapeutics by 6.3% during the second quarter. Dimensional Fund Advisors LP now owns 1,417,472 shares of the company's stock worth $32,913,000 after purchasing an additional 84,522 shares during the period. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Denali Therapeutics

In related news, insider Alexander O. Schuth sold 15,558 shares of the business's stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $29.91, for a total value of $465,339.78. Following the completion of the transaction, the insider now directly owns 178,066 shares in the company, valued at $5,325,954.06. The trade was a 8.04 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Ryan J. Watts sold 40,000 shares of the stock in a transaction on Friday, October 18th. The shares were sold at an average price of $27.69, for a total value of $1,107,600.00. Following the sale, the chief executive officer now owns 235,807 shares in the company, valued at approximately $6,529,495.83. This represents a 14.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 86,578 shares of company stock valued at $2,474,440 in the last quarter. 7.90% of the stock is owned by insiders.

Denali Therapeutics Stock Performance

Shares of Denali Therapeutics stock traded down $0.07 during trading on Tuesday, hitting $23.22. The company's stock had a trading volume of 1,408,231 shares, compared to its average volume of 1,053,083. Denali Therapeutics Inc. has a 52 week low of $14.56 and a 52 week high of $33.33. The company has a market capitalization of $3.34 billion, a PE ratio of -8.41 and a beta of 1.35. The company has a fifty day simple moving average of $26.21 and a two-hundred day simple moving average of $24.88.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.03). During the same period in the previous year, the company earned ($0.72) earnings per share. As a group, analysts predict that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on DNLI shares. HC Wainwright restated a "buy" rating and set a $90.00 price target on shares of Denali Therapeutics in a report on Thursday, November 7th. Raymond James reissued a "market perform" rating on shares of Denali Therapeutics in a research note on Thursday, October 10th. Stifel Nicolaus upgraded Denali Therapeutics from a "hold" rating to a "buy" rating and set a $37.00 target price for the company in a report on Monday. JPMorgan Chase & Co. cut their price target on shares of Denali Therapeutics from $29.00 to $28.00 and set an "overweight" rating on the stock in a report on Friday, October 11th. Finally, Jefferies Financial Group upped their price objective on shares of Denali Therapeutics from $40.00 to $45.00 and gave the stock a "buy" rating in a report on Friday, November 1st. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, Denali Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $40.40.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.